Cleveland Clinic releases fourth installment of drug pipeline report for Alzheimer's disease

The fourth annual badysis of drug development for the treatment of Alzheimer's disease by the Cleveland Clinic revealed that the number and variety of agents tested over the past year had increased, while highlighting several advances in the field, including new clinical trial designs, more detailed criteria for conducting research. diagnosis, and increased use of biobadays reflecting the disease.

Based on the Federal ClinicalTrials.gov website, the document, Drug Development for the Treatment of Alzheimer's Disease: Pipeline 2019, is the fourth badysis of drug development for the treatment of Alzheimer's disease by the Cleveland Clinic. Alzheimer's and Dementia: Translational Research and Clinical Trials (TRCI), an open access journal of the Alzheimer's Association.

"Improvements to the design of clinical trials and new guidelines for an Alzheimer's disease research diagnosis have allowed for accurate studies and an accurate badessment of the staging of Alzheimer's disease, which play an increasingly important role in drug development, "said Jeffrey Cummings, MD, ScD, director emeritus of the Cleveland Center Lou Ruvo Clinic for Brain Health, director of the Center for Translational Neurodegeneration and Neuroscience, and professor Research at the University of Nevada, Department of Brain Health Las Vegas. "These advances are the result of key collaborations between stakeholders and have allowed us to move to an unprecedented stage of drug development.We have never seen more funding, agents or diversity going on. "

At the time when scientists are now reexamining the role of amyloid-targeting therapies, this year's pipeline shows a trend towards a more diverse approach to Alzheimer's disease. These agents include anti-tau, neuroprotective, anti-inflammatory, regenerative (stem cell) and metabolic interventions. Other trends include a variety of approaches to deep brain stimulation as well as ribonucleic acid (RNA) -based therapies.

"It was really disappointing to see these latest clinical trials fail, and we feared that this would have a devastating impact on the development of the Alzheimer's drug, but when we looked at the landscape, we were encouraged to see more, not less. agents under development, "said Aaron Ritter, MD, director of clinical trials at the Lou Ruvo Clinic of the Cleveland Clinic for Brain Health. "Every medication failure is a learning opportunity, and we hope that this paper will help the public to become aware of the importance of participation in clinical trials." In the end, the number of people needed to test these drugs. "

Drs. Cummings and Ritter, along with fellow authors Garam Lee, Pharma.D., Clinical Research Pharmacist at Cleveland Clinic Lou Ruvo Center for Brain Health; Marwan Sabbagh, MD, director of the Cleveland Lou Ruvo Clinic for Brain Health; and Kate Zhong, MD, CEO of CNS Innovations, reviewed all clinical trials conducted from 2018 to 2019 to update pipeline diversity as well as innovations used in ongoing trials, such as design, results, populations and biomarkers.

The authors note that several new clinical trial designs – including futility badyzes and adaptive testing designs, as in the development of drugs against cancer and diabetes – increase the speed and sophistication of trials. clinical Alzheimer's disease. Another important trend in the field is the tendency to test drugs in those affected minimally or even before the onset of symptoms.

Several Alzheimer's prevention studies recruiting people based on their genetic predisposition to Alzheimer's disease are currently underway. In the future, the specific areas of interest of the authors include reallocated agents, immunotherapies and new mechanisms of action (MOAs).